Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia

Heart Rhythm

Volumn 10, Issue 11, 2013, Pages 1671-1675

  Khoury, Asaad ^a   Marai, Ibrahim ^a,b   Suleiman, Mahmoud ^b   Blich, Miry ^b   Lorber, Avraham ^a   Gepstein, Lior ^b   Boulos, Monther ^b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b Rambam Health Care Campus   (Israel)

Author keywords

Calsequestrin; Catecholaminergic polymorphic ventricular tachycardia; Flecainide

Indexed keywords

CALSEQUESTRIN; FLECAINIDE; PROPRANOLOL; VERAPAMIL;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR RISK; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG TOLERABILITY; EXERCISE INDUCED VENTRICULAR ARRHYTHMIA; EXERCISE TEST; FAINTNESS; FEMALE; FOLLOW UP; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MALE; MEDICATION THERAPY MANAGEMENT; PRIORITY JOURNAL;

CALSEQUESTRIN; CALSEQUESTRIN-ASSOCIATED CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CASQ2; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CPVT; CPVT2; EIVA; EXERCISE-INDUCED VENTRICULAR ARRHYTHMIAS; FLECAINIDE; ICD; IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; RYANODINE RECEPTOR; RYR2; VENTRICULAR TACHYCARDIA; VT;

ADOLESCENT; ANTI-ARRHYTHMIA AGENTS; CALSEQUESTRIN; DEATH, SUDDEN, CARDIAC; DNA; ELECTROCARDIOGRAPHY; EXERCISE TEST; FEMALE; FLECAINIDE; FOLLOW-UP STUDIES; HUMANS; MALE; MUTATION; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84886992875     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2013.08.011     Document Type: Article

References (10)

1. G. Katz, M. Arad, and M. Eldar Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyond Curr Probl Cardiol 34 2009 9 43
2. A. Leenhardt, V. Lucet, I. Denjoy, F. Grau, D.D. Ngoc, and P. Coumel Catecholaminergic polymorphic ventricular tachycardia in children: a 7-year follow-up of 21 patients Circulation 91 1995 1512 1519
3. U. Mohamed, M.H. Gollob, R.M. Gow, and A.D. Krahn Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia Heart Rhythm 3 2006 1486 1489
4. C. van der Werf, P.J. Kannankeril, and F. Sacher Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia J Am Coll Cardiol 57 2011 2244 2254
5. H. Lahat, M. Eldar, and E. Levy-Nissenbaum Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21 Circulation 103 2001 2822 2827
6. H. Lahat, E. Pras, and T. Olender A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel Am J Hum Genet 69 2001 1378 1384
7. H. Watanabe, N. Chopra, and D. Laver Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans Nat Med 15 2009 380 383
8. C. Pott, D.G. Dechering, and F. Reinke Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature Europace 13 2011 897 901
9. H. Watanabe, C. van der Werf, and F. Roses-Noguer Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia Heart Rhythm 10 2013 542 547
10. I. Marai, A. Khoury, and M. Suleiman Importance of ventricular tachycardia storms not terminated by implantable cardioverter defibrillators shocks in patients with CASQ2 associated catecholaminergic polymorphic ventricular tachycardia Am J Cardiol 110 2012 72 76